Compare Recursion Pharmaceuticals Inc (RXRX) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Energy Select Sector SPDR Fund — how do they compare? Recursion Pharmaceuticals Inc trades at $3.25 (market cap $1.86B), while Energy Select Sector SPDR Fund trades at $65.5. The key difference: Energy Select Sector SPDR Fund is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | XLE | |
|---|---|---|
Market Cap | $1.86B | — |
Sector | Health | — |
52-Week High | $6.79 | $65.31 |
52-Week Low | $2.84 | $42.61 |
Enterprise Value | $1.38B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
XLE trades at $64.78, up 1.12% with strong bullish technical signals from moving averages. The ETF benefits from oil price strength above $100/barrel and geopolitical tensions in the Middle East. Recent performance shows XLE gained 7.4% in August, leading sector ETFs. Technical indicators show RSI at 78.15 suggests overbought conditions while ADX indicates strong trend momentum.
Outlook remains positive given energy sector tailwinds from supply constraints and winter demand, though elevated oil prices create both opportunity and volatility risk. The ETF's concentrated holdings in major energy companies provide leveraged exposure to crude price movements, with valuations reflecting long-term oil prices below current spot levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
